Cargando…

Eicosapentaenoic Acid Inhibits KRAS Mutant Pancreatic Cancer Cell Growth by Suppressing Hepassocin Expression and STAT3 Phosphorylation

Background: The oncogenic Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation was reported to be the signature genetic event in most cases of pancreatic ductal adenocarcinoma (PDAC). Hepassocin (HPS/FGL1) is involved in regulating lipid metabolism and the progression of several cancer types;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiu, Ching-Feng, Hsu, Ming-I, Yeh, Hsiu-Yen, Park, Ji Min, Shen, Yu-Shiuan, Tung, Te-Hsuan, Huang, Jun-Jie, Wu, Hung-Tsung, Huang, Shih-Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001293/ https://www.ncbi.nlm.nih.gov/pubmed/33801246 http://dx.doi.org/10.3390/biom11030370

Ejemplares similares

Compensatory Increase of Serum Hepassocin Protects Hyperthyroidism-Induced Hepatic Dysfunction
por: Wang, Chih-Chen, et al.
Publicado: (2023)

Circulating hepassocin level in patients with stable angina is associated with fatty liver and renal function
por: Tsai, I-Ting, et al.
Publicado: (2021)

Protective Role of Hepassocin against Hepatic Endoplasmic Reticulum Stress in Mice
por: Yang, Yang, et al.
Publicado: (2022)

Eicosapentaenoic acid prevents arterial calcification in klotho mutant mice
por: Nakamura, Kazufumi, et al.
Publicado: (2017)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer
por: D’Amico, Stephen, et al.
Publicado: (2023)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Astaxanthin and eicosapentaenoic acid production by S4, a new mutant strain of Nannochloropsis gaditana
por: Cecchin, Michela, et al.
Publicado: (2022)

Transcriptome Analysis Reveals an Eicosapentaenoic Acid Accumulation Mechanism in a Schizochytrium sp. Mutant
por: Ou, Ying, et al.
Publicado: (2023)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Prostate Cancer Cell Migration and Invasion Induced by Tumor-Associated Macrophages
por: Li, Cheng-Chung, et al.
Publicado: (2014)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8
por: Wang, Hao-Chen, et al.
Publicado: (2019)

Effects of Caloric Restriction with Protein Supplementation on Plasma Protein Profiles in Middle-Aged Women with Metabolic Syndrome—A Preliminary Open Study
por: Chang, Chia-Yu, et al.
Publicado: (2019)

Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation
por: Shen, Chih-Jie, et al.
Publicado: (2023)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Retraction: Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Prostate Cancer Cell Migration and Invasion Induced by Tumor-Associated Macrophages
por: Li, Cheng-Chung, et al.
Publicado: (2017)

STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway
por: Wang, Zhenlin, et al.
Publicado: (2019)

Tyrosine phosphorylation of lamin A by Src promotes disassembly of nuclear lamina in interphase
por: Chu, Ching-Tung, et al.
Publicado: (2021)

Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis
por: Weng, Ching-Chieh, et al.
Publicado: (2018)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

A Taiwanese food frequency questionnaire correlates with plasma docosahexaenoic acid but not with plasma eicosapentaenoic acid levels: questionnaires and plasma biomarkers
por: Chien, Kuo-Liong, et al.
Publicado: (2013)

CSF2 Overexpression Is Associated with STAT5 Phosphorylation and Poor Prognosis in Patients with Urothelial Carcinoma
por: Lee, Yi-Ying, et al.
Publicado: (2016)

Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells
por: Hara, Toshifumi, et al.
Publicado: (2014)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling
por: Luo, Yuan-Deng, et al.
Publicado: (2022)

N-3 PUFA Ameliorates the Gut Microbiota, Bile Acid Profiles, and Neuropsychiatric Behaviours in a Rat Model of Geriatric Depression
por: Tung, Te-Hsuan, et al.
Publicado: (2022)

An Increase in Phosphorylation and Truncation of Crystallin With the Progression of Cataracts()
por: Lin, Hui-Ju, et al.
Publicado: (2013)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

Mutant KRAS promotes malignant pleural effusion formation
por: Αgalioti, Theodora, et al.
Publicado: (2017)

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
por: Nollmann, Friederike Inga, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f2oocsdu4ibhbs4v5fmv3eiuan